MCP-1 binding nucleic acids and use thereof
The present invention is related to a nucleic acid molecule capable of binding to MCP-1, whereby the nucleic acid molecule is for use as a medicament for the treatment and/or prevention of a chronic disease or chronic disorder, preferably selected from the group consisting of chronic respiratory disease, chronic kidney disease and systemic lupus erythematosus.
1. A treatment composition comprising two active agents consisting of (1) an L nucleic acid comprising SEQ ID NO:37 or a homolog thereof with at least 85% homology thereto and (2) a cyclophosphamide.
2. The composition of claim 1 , wherein SEQ ID NO:37 or homolog thereof binds monkey MCP-1, horse MCP-1, rabbit MCP-1, bovine MCP-1, canine MCP-1, porcine MCP-1 or human MCP-1.
3. The composition according to claim 1 , wherein SEQ ID NO:37 or homoloq thereof binds a human MCP-1.
4. The composition according to claim 1 , wherein SEQ ID NO:37 or homolog thereof binds the amino acid sequence according to SEQ ID NO:1.
5. The composition according to claim 1 , wherein SEQ ID NO:37 or homolog thereof comprises a modification.
6. The composition according to claim 5 , wherein the modification is selected from the group consisting of a HES moiety, a PEG moiety, a biodegradable modification and combinations thereof.
7. The composition according to claim 6 , wherein the PEG moiety comprises a straight or branched PEG.
8. The composition according to claim 6 , wherein the modification is a HES moiety.
9. The composition according to claim of 5 , wherein the modification is coupled to SEQ ID NO:37 or homolog thereof via a linker.
10. The composition of claim 6 , wherein said PEG moiety is at the 5′ terminus of SEQ ID NO:37 or homolog thereof.
11. The composition of claim 6 , wherein said PEG moiety is at the 3′ terminus of SEQ ID NO:37 or homolog thereof.
12. The composition of claim 6 , wherein said PEG moiety is from about 2 kD to about 200 kD.
13. The composition of claim 6 , wherein said PEG moiety is from about 40 kD to about 120 kD.
14. The composition of claim 1 , wherein said active agents are contained in a single vessel.